These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 10972478)

  • 1. Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin.
    Vaidyanathan S; Boroujerdi M
    Cancer Chemother Pharmacol; 2000; 46(2):93-100. PubMed ID: 10972478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of tamoxifen pretreatment on the pharmacokinetics, metabolism and cardiotoxicity of doxorubicin in female rats.
    Vaidyanathan S; Boroujerdi M
    Cancer Chemother Pharmacol; 2000; 46(3):185-92. PubMed ID: 11021735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
    Schroeder PE; Hasinoff BB
    Drug Metab Dispos; 2005 Sep; 33(9):1367-72. PubMed ID: 15980099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dexrazoxane on doxorubicin pharmacokinetics in young and old rats.
    Cusack BJ; Musser B; Gambliel H; Hadjokas NE; Olson RD
    Cancer Chemother Pharmacol; 2003 Feb; 51(2):139-46. PubMed ID: 12647015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
    Schroeder PE; Hasinoff BB
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):509-13. PubMed ID: 12451479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin.
    Darvari R; Boroujerdi M
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):497-509. PubMed ID: 15937726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
    Malisza KL; Hasinoff BB
    Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
    Hasinoff BB; Schroeder PE; Patel D
    Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane (ICRF-198) and d-1,2-bis(3,5-dioxopiperazine-1-yl)propane (ICRF-187) inhibition of Fe3+ reduction, lipid peroxidation, and CaATPase inactivation in heart microsomes exposed to adriamycin.
    Vile GF; Winterbourn CC
    Cancer Res; 1990 Apr; 50(8):2307-10. PubMed ID: 2156615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
    Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
    Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane.
    Della Torre P; Mazué G; Podestà A; Moneta D; Sammartini U; Imondi AR
    Cancer Chemother Pharmacol; 1999; 43(2):151-6. PubMed ID: 9923821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effect of dioxopiperazine compounds on malondialdehyde formation induced by doxorubicin in rat liver mitochondria in vitro.
    Zhang Y; Hua HY; Zhang TM
    Zhongguo Yao Li Xue Bao; 1993 Jul; 14(4):340-3. PubMed ID: 8249630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
    Wu X; Patel D; Hasinoff BB
    J Inorg Biochem; 2004 Nov; 98(11):1818-23. PubMed ID: 15522409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood.
    Schroeder PE; Wang GQ; Burczynski FJ; Hasinoff BB
    Drug Metab Dispos; 2005 Jun; 33(6):719-25. PubMed ID: 15764716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
    Hasinoff BB
    Cardiovasc Toxicol; 2002; 2(2):111-8. PubMed ID: 12271154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselective metabolism of dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
    Hasinoff BB; Aoyama RG
    Chirality; 1999; 11(4):286-90. PubMed ID: 10224655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog.
    Baldwin JR; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK
    Cancer Chemother Pharmacol; 1992; 30(6):433-8. PubMed ID: 1394799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
    Ramanathan-Girish S; Boroujerdi M
    J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The iron chelator Dp44mT does not protect myocytes against doxorubicin.
    Hasinoff BB; Patel D
    J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction.
    Thomas C; Vile GF; Winterbourn CC
    Biochem Pharmacol; 1993 May; 45(10):1967-72. PubMed ID: 8390256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.